The nasty rhetoric between DuPont and Trian Fund Management has been ramped up in the days leading up to next week’s proxy vote.
But whether or not Nelson Peltz‘s effort to get four members onto the DuPont board are successful, a couple interesting developments have taken place.
Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
One, the two sides are not nearly as far apart as they were when this proxy war began.
And two, no matter who gains a seat on DuPont’s board, it appears the company will emerge more efficient… [READ MORE]
By Jeff Mordock
